PKI - PerkinElmer to acquire Nexcelom for $260 Million

PerkinElmer (PKI) has agreed to acquire private-held Nexcelom Bioscience for $260M in cash.Headquartered in Lawrence, Massachusetts Nexcelom is a developer and marketer of image cytometry products for cell analysis.The company with ~130 employees, has operations in the U.S., the UK, and China. The transaction is expected to close in Q2 2021.Commenting on the acquisition, PerkinElmer CEO Prahlad Singh said: “We are looking forward to bringing Nexcelom’s expertise and technologies in drug development together with our passion and solutions for drug discovery.”In November 2020, PerkinElmer announced an agreement to acquire Horizon Discovery Group for $383M.In Q1 2021, the Cash and cash equivalents at the company more than doubled from 2020-year end to reach $988.2M.

For further details see:

PerkinElmer to acquire Nexcelom for $260 Million